Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing a downturn in stock indices, yet there is significant capital inflow into innovative drug ETFs, indicating a potential investment opportunity in the long term [1]. Group 1: Market Performance - The CSI Hong Kong Stock Connect Healthcare Comprehensive Index fell by 4.7%, while the Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 4.3% [1]. - The CSI Innovative Drug Industry Index declined by 1.5%, and the CSI Biotechnology Theme Index dropped by 1.2% [1]. - The CSI 300 Healthcare Index saw a smaller decline of 0.8% [1]. - Despite the overall market downturn, the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) recorded a net subscription of 34 million units throughout the day [1]. Group 2: Industry Growth and Valuation - The total value of License-out transactions for Chinese innovative drugs has increased from $2.562 billion in 2017 to $140.274 billion by 2025, reflecting enhanced international competitiveness [1]. - By 2025, over 70% of innovative drug companies are expected to achieve positive revenue growth, indicating that the industry is entering a commercialization phase [1]. - The current valuation of the pharmaceutical sector is considered attractive, with recommendations to focus on companies with clear overseas expansion opportunities and those with clinical data advantages in specific segments [1].

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 3.7%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 3.1% [1] - The total value of China’s innovative drug License-out transactions grew from $2.562 billion in 2017 to $140.274 billion by 2025, indicating enhanced international competitiveness [1] - Over 70% of innovative drug companies are expected to achieve positive revenue growth by 2025, marking a transition into a commercialization phase for the industry [1] Group 2 - The current valuation of the pharmaceutical sector is considered attractive, with a recommendation to focus on companies with clear overseas expansion opportunities and those with clinical data advantages in specific segments [1] - The ETF tracking the CSI Biotechnology Theme Index, managed by E Fund, has seen a decline of 0.3% [4] - The ETF tracking the CSI Pharmaceutical and Health Index, also managed by E Fund, has similarly decreased by 0.3% [4]

Core Viewpoint - The Hong Kong Stock Connect Technology ETF, Haitong (513860), has shown a slight pullback, but the underlying fundamentals remain strong, with significant net inflows and attractive valuation metrics [1][2] Group 1: Market Performance - As of February 13, 2026, the Hong Kong Stock Connect Technology ETF, Haitong (513860), experienced a minor decline, while several constituent stocks, including Jiufang Zhitu Holdings, rose over 5% [1] - Notable gains were also observed in companies such as Zai Lab, Lenovo Group, and China National Pharmaceutical Group, each increasing by over 1% [1] - The net inflow for the ETF has increased by 321 million yuan over the past three months and by 1.826 billion yuan over the last six months, indicating significant long-term growth [1] Group 2: Valuation Metrics - The latest price-to-earnings ratio (PE-TTM) for the index tracked by the ETF is 23.87 times, and the price-to-book ratio (MRQ) is 3.68 times, both of which are at historical lows [1] - The overall earnings expectations for the Hang Seng Index have been moderately adjusted upwards, contributing to its recent resilience [1] Group 3: Sector Analysis - China Galaxy Securities reports that the technology sector remains a key focus for medium to long-term investments, with reduced valuation pressure following recent pullbacks, suggesting potential for rebound [1] - The top five sectors within the index include Consumer Discretionary (37.02%), Information Technology (27.98%), Healthcare (17.17%), Communication Services (16.31%), and Industrials (1.52%) [2]

Core Viewpoint - The Hong Kong stock market indices related to consumption, healthcare, and new economy sectors experienced declines, with the consumer theme index down by 1.2%, the healthcare index down by 1.4%, and the new economy index down by 1.5% [1]. Group 1: Market Performance - The Hang Seng Technology Index and the CSI Hong Kong Stock Connect Internet Index both fell by 1.7% [1]. - The recent 10 trading days saw net inflows of 2.3 billion yuan into the E Fund Hang Seng Technology ETF (513010) and 800 million yuan into the E Fund Hong Kong Stock Connect Internet ETF (513040), both reaching record high sizes since their inception [1]. Group 2: Index Composition - The CSI Hong Kong Stock Connect Consumer Theme Index consists of 50 major consumer stocks with good liquidity and large market capitalization, with a significant portion in consumer discretionary [4]. - The index has a rolling price-to-earnings ratio of 18.6 times and a valuation percentile of 4.4% since its inception in 2020 [4].

Core Viewpoint - The pharmaceutical industry is experiencing growth due to persistent human demand and unmet needs, alongside increased R&D investments by companies, marking the transition to an "innovation-driven" revenue era in China [1]. Group 1: Index Performance - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rose by 2.1% [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 2.0% [1]. - The CSI Biotechnology Theme Index saw a rise of 0.6% [1]. - The CSI Innovative Drug Industry Index grew by 0.4% [1]. - The CSI 300 Pharmaceutical and Health Index experienced a slight increase of 0.2% [1]. Group 2: Index Composition - The index focuses on leading innovative drug companies in A-shares, comprising no more than 50 stocks involved in innovative drug R&D [5]. - The index tracks leading biotechnology companies in A-shares, including no more than 50 stocks related to gene diagnostics, biopharmaceuticals, and other human biotechnology [7]. - The index covers leading companies in the pharmaceutical and health industry within the CSI 300, including segments like chemical pharmaceuticals, medical services, and medical devices [9]. Group 3: Valuation Metrics - The rolling P/E ratio for the innovative drug index is 50.4 times, with a valuation increase of 72.3% since its inception [6]. - The rolling P/E ratio for the biotechnology index is 53.2 times, with a valuation increase of 58.7% since its inception [8]. - The rolling P/E ratio for the CSI 300 Pharmaceutical and Health Index is 29.9 times, with a valuation increase of 39.2% since its inception [10].

Core Viewpoint - The Hong Kong stock market showed mixed performance on February 4, with active movements in the consumer, real estate, and innovative pharmaceutical sectors, while large technology stocks collectively declined. Southbound funds recorded a net purchase exceeding 13 billion HKD throughout the day. Group 1: Market Performance - The consumer theme index under the China Securities Hong Kong Stock Connect rose by 1.0% [1] - The China Securities Hong Kong Stock Connect medical and health comprehensive index increased by 0.5% [1] - The Hang Seng New Economy Index fell by 0.9% [1] - The Hang Seng Technology Index decreased by 1.8% [1] - The China Securities Hong Kong Stock Connect Internet Index dropped by 2.4% [1] Group 2: Index Composition - The consumer theme index consists of 50 large-cap consumer stocks within the Hong Kong Stock Connect, with over 65% of the index composed of discretionary consumption [4] - The rolling price-to-earnings ratio of the consumer theme index is 17.7 times, with a valuation percentile of 1.9% since its inception in 2020 [4]

Core Points - The Ministry of Education has launched the "Winter Employment Warm Action" to promote high-quality employment for 2026 college graduates during the winter break [1] - The National College Student Employment Service Platform will host 15 key recruitment events focusing on various industries and regions to connect graduates with employers [1][2] Recruitment Events Summary - "Rural Revitalization: Great Opportunities" recruitment fair will focus on agriculture, forestry, and cultural tourism, providing approximately 30,000 job positions until January 31, 2026 [2] - "2026 National Undergraduate Recruitment Fair" aims to connect undergraduate graduates with employers, offering around 60,000 job positions until February 28, 2026 [3] - "Automotive Industry Recruitment Fair" will provide 50,000 job positions for graduates interested in the automotive sector, lasting until January 31, 2026 [4] - "2026 National Graduate Online Recruitment Month" will focus on high-level talent, offering 50,000 job positions until February 15, 2026 [5] - "Winter Internship Recruitment Fair" will provide 20,000 job positions for students seeking internships, lasting until January 31, 2026 [6] - "Information and Communication Industry Winter Recruitment Fair" will offer 10,000 job positions until February 28, 2026 [7] - "National Pharmaceutical and Health Industry Winter Recruitment Fair" will focus on job matching for graduates, providing 10,000 positions until March 31, 2026 [9] - "'Warm Heart Delivery' Equipment Manufacturing Industry Recruitment Fair" will provide 30,000 job positions until March 1, 2026 [10] - "Belt and Road" recruitment fair will offer around 50,000 job positions until February 28, 2026 [11] - "Western Region Graduate Recruitment Fair" will provide 30,000 job positions until February 28, 2026 [12] - "Northeast Five Universities Recruitment Fair" will focus on regional talent matching, offering 20,000 job positions until March 9, 2026 [13] - "Yangtze River Delta Graduate Recruitment Fair" will provide diverse job opportunities until March 15, 2026 [14] - "Xinjiang Region and Xinjiang Graduates Recruitment Fair" will offer 20,000 job positions from January 27 to March 31, 2026 [15] - "Winter Warm Employment Joint Recruitment Activity" will provide 50,000 job positions from February 5 to March 15, 2026 [16] - "Together We Build" recruitment fair for ethnic minority graduates will offer 20,000 job positions from February 24 to March 24, 2026 [18]

Core Viewpoint - The pharmaceutical sector experienced a collective pullback today, with various indices showing declines, while there is still significant capital inflow into innovative drug ETFs, indicating a potential recovery in demand for CRO and CDMO services [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 1.4% [1]. - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index and the CSI Innovative Drug Industry Index both decreased by 1.1% [1]. - The CSI Biotechnology Theme Index dropped by 0.8%, and the CSI 300 Pharmaceutical and Health Index declined by 0.7% [1]. - Despite the overall market decline, the E Fund Innovative Drug ETF (159316) saw a net subscription of over 20 million units throughout the day [1]. Group 2: Industry Outlook - According to Zhongtai Securities, multiple factors are driving a gradual recovery in demand for CRO and CDMO services within the pharmaceutical sector [1]. - The past three years have seen a continuous clearing of supply, suggesting that the sector may experience a "Davis Double Play" with simultaneous improvements in profitability and valuation [1].

Core Viewpoint - The recent decline of over 2.5% in the Sci-Tech Innovation and Entrepreneurship ETF (588360) presents significant structural opportunities in the Sci-Tech sector, suggesting that this pullback may be a good time for investment [1]. Group 1: Market Conditions - According to Dongfang Securities, Sci-Tech enterprises are currently in a strong prosperity cycle amid a capital expenditure cycle [1]. - Overall domestic liquidity is ample, with funds concentrating on high-prosperity sectors, indicating a prevalence of structural opportunities [1]. Group 2: Strategic Focus - Bank of China International highlights that the year marks the beginning of the "14th Five-Year Plan," with technological self-reliance and advanced manufacturing expected to be core themes [1]. - The technology sector needs to shift towards systematic allocation, covering key core technologies and high-end manufacturing across multiple directions [1]. - Advanced manufacturing is set to upgrade to a multi-layered system, focusing on future industry layouts [1]. Group 3: ETF Overview - The Sci-Tech Innovation and Entrepreneurship ETF (588360) tracks the Sci-Tech Innovation 50 Index (931643), which has a daily price fluctuation limit of 20% [1]. - This index selects 50 listed companies with larger market capitalizations and better liquidity from the Sci-Tech Board and the Growth Enterprise Market, reflecting the overall performance of securities related to technological innovation [1]. - The index sample covers multiple industries, including information technology and healthcare, aiming to highlight the innovation capabilities and growth potential of enterprises [1].

Group 1 - The core viewpoint of the news is that the Medical ETF (512170) has experienced a decline of 1.61%, with the latest price at 0.366 yuan and a turnover rate of 2.25% [1] - The Medical ETF closely tracks the CSI Medical Index, which includes companies involved in medical devices, medical services, and medical information technology [1] - The latest scale of the Medical ETF is 26.117 billion yuan, with a total of 70.245 billion shares, indicating an increase of 524 million yuan in fund size over the past month [1] Group 2 - As of the previous trading day, the Medical ETF (512170) saw a net inflow of 26.1418 million yuan [2] - The top ten weighted stocks in the CSI Medical Index include WuXi AppTec, Mindray Medical, United Imaging Healthcare, Aier Eye Hospital, Kanglong Chemical, Tigermed, Lepu Medical, Yuyue Medical, New Industry, and Meinian Onehealth [2]